Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration

被引:10
作者
Aviles, P
Pateman, A
Roman, RS
Guillen, MJ
De las Heras, FG
Gargallo-Viola, D
机构
[1] GlaxoSmithKline, Madrid 28760, Spain
[2] GlaxoSmithKline Res & Dev, Stevenage SG1 2NY, Herts, England
基金
英国惠康基金;
关键词
D O I
10.1128/AAC.45.10.2787-2792.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Sordarin derivatives constitute a new group of synthetic antifungal agents that selectively inhibit fungal protein synthesis. They have demonstrated in vitro activity against the most important fungal pathogens, both yeast and filamentous. This new family of compounds has also shown in vivo activity against murine Candida albicans, Histoplasma capsulatum, and Coccidioides immitis experimental infections, as well as against Pneumocystis carinii pneumonia in rats. After intravenous dosing in animals, both the area under the concentration-time curve and the elimination half-life were highest in Cynomolgus monkeys, followed by those in rats, mice, and rabbits. The volume of distribution at steady state for sordarin derivatives was similar in all species tested. The clearance in rats and mice was higher than for other species. GM 237354, a sordarin derivative, was characterized by high serum protein binding in mouse, rat, and monkey serum (unbound fraction, less than or equal to5%). An indirect evaluation of the effect of liver function upon the metabolism of this class of compounds has been made in animals with impaired liver function such as Gunn rats, as well as in allometric studies that showed better correlations of half-life to liver blood flow than to animal body weight. Linearity of the main pharmacokinetic parameters was demonstrated after intravenous dosing of the representative compound GM 193663 at 10 and 20 mg/kg of body weight in rats. Allometry was used to determine whether human pharmacokinetic parameters can be predicted from animal data by regression analysis against body weight and liver blood flow. All these results have demonstrated that the human pharmacokinetics of sordarin derivatives can be forecast from animal data.
引用
收藏
页码:2787 / 2792
页数:6
相关论文
共 25 条
[1]   In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats [J].
Aviles, P ;
Aliouat, EM ;
Martinez, A ;
Dei-Cas, E ;
Herreros, E ;
Dujardin, L ;
Gargallo-Viola, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) :1284-1290
[2]   Pharmacokinetics-pharmaco dynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis [J].
Aviles, P ;
Falcoz, C ;
San Roman, R ;
Gargallo-Viola, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2333-2340
[3]   INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM [J].
BOXENBAUM, H .
DRUG METABOLISM REVIEWS, 1984, 15 (5-6) :1071-1121
[4]   INTERSPECIES SCALING, ALLOMETRY, PHYSIOLOGICAL TIME, AND THE GROUND PLAN OF PHARMACOKINETICS [J].
BOXENBAUM, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (02) :201-225
[5]   Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis [J].
Clemons, KV ;
Stevens, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1874-1877
[6]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[7]   BIOTRANSFORMATION AND TOXICITY OF ACETAMINOPHEN IN CONGENIC RHA RATS WITH OR WITHOUT A HEREDITARY-DEFICIENCY IN BILIRUBIN UDP GLUCURONOSYLTRANSFERASE [J].
DEMORAIS, SMF ;
CHOW, SYM ;
WELLS, PG .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1992, 117 (01) :81-87
[8]   Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans [J].
Domínguez, JM ;
Martín, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2279-2283
[9]   Sordarins:: A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts [J].
Domínguez, JM ;
Kelly, VA ;
Kinsman, OS ;
Marriott, MS ;
De Las Heras, FG ;
Martín, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2274-2278
[10]   ROLE OF PHARMACOKINETICS IN THE OUTCOME OF INFECTIONS [J].
DRUSANO, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (03) :289-297